ReviewJournal of anesthesia and translational medicine2024
Perfluorocarbon-based oxygen carriers: What is new in 2024?
Review in Journal of anesthesia and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Perfluorocarbon-based artificial oxygen carriers in perioperative and surgical care: a scoping review of basic and translational studies.Frontiers in medicine · 2026Pooled it
- Hemoglobin-based oxygen carrier: what we have learned and where we are heading?Protein & cell · 2026Article
- Artificial Blood and Stem Cell-Derived Oxygen Therapeutics in Oncology: Emerging Strategies for Overcoming Tumor Hypoxia.Stem cell reviews and reports · 2026Review
- Cocktail-style multifunctional resuscitation fluids: Where are we now in 2026?Journal of anesthesia and translational medicine · 2026Review
- The evolution of artificial red blood cells and recent advances in state-of-the-art oxygen carrier technologies: a narrative review.Blood science (Baltimore, Md.) · 2025Review
- Revolutionizing cancer care: Bioprinting prostate cancer stem cells for targeted treatments.World journal of clinical oncology · 2025Review
- Progress in Development of Functional Biological and Synthetic Blood Products to Augment Transfusable Blood Supply in Operational Medicine.Bioengineering (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perflurocarbon-based oxygen carriers (PBOC) represent a major category of artificial oxygen therapeutics. Since their initial report of potential oxygen-carrying capability half a century ago, some PBOC products have been developed for the purpose of oxygen therapeutics. Unfortunately, the majority of these products have been discontinued due to side effects, such as Flusol-DA-20, Oxygent, and Oxycyte. PBOC is unique due to its inorganic nature and relatively smaller molecules, making it possible to production in massive quantity. Perftoran was developed in Moscow, Russia, and approved for clinical use in Russia and Mexico from 2005 to 2010. Perftoran had been administered to over 35,000 patients with purportedly relatively mild adverse effects. Thus, FluorO2 Therapeutics, Inc. is rebranding and investigating it for the North America market. PHER-O2 is undergoing active translational research, with the goal of reaching clinical stages of application. Albumin-derived perfluorocarbon-based artificial oxygen carriers are the newest development in PBOC field of blood substitute/oxygen therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.